INVO Bioscience (NASDAQ:INVO) & Bluejay Diagnostics (NASDAQ:BJDX) Financial Analysis
INVO Bioscience (NASDAQ:INVO – Get Rating) and Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) are both small cap medical companies, but which is the best investment? We’ll compare the two companies based on earnings strength, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
21.7% of INVO Bioscience shares are held by institutional investors. By comparison, 45.4% of shares in Bluejay Diagnostics are held by institutional investors. 7.6% of INVO Bioscience shares are held by insiders of the company. By comparison, 45.3% of shares in Bluejay Diagnostics are held by insiders of the company. Strong institutional ownership indicates that large fund managers, endowments, and hedge funds believe a stock is poised for long-term growth.
This table compares the net margins, return on equity and return on assets of INVO Bioscience and Bluejay Diagnostics.
|Net margins||Return on equity||return on assets|
|Diagnosis Bluejay||N / A||N / A||N / A|
Benefits and evaluation
This table compares the gross revenue, earnings per share and valuation of INVO Bioscience and Bluejay Diagnostics.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|INVO Biosciences||$4.16 million||2.62||-$6.66 million||N / A||N / A|
|Diagnosis Bluejay||N / A||N / A||-3.49 million dollars||N / A||N / A|
Bluejay Diagnostics has lower revenues, but higher revenues than INVO Bioscience.
This is a summary of recent ratings and target prices for INVO Bioscience and Bluejay Diagnostics, as reported by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
INVO Bioscience currently has a consensus price target of $2.50, indicating a potential upside of 177.78%. Bluejay Diagnostics has a consensus price target of $10.00, indicating 900.20% upside potential. Given Bluejay Diagnostics’ higher consensus rating and higher possible upside, analysts clearly believe that Bluejay Diagnostics is more favorable than INVO Bioscience.
Bluejay Diagnostics beats INVO Bioscience on 8 out of 10 factors compared between the two stocks.
About INVO Bioscience (Get a rating)
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryonic development to take place in vivo in the female body. The company was founded in 2007 and is based in Sarasota, Florida.
About Bluejay Diagnostics (Get a rating)
Bluejay Diagnostics, Inc., a diagnostics company, develops and markets patient-directed products for the triage, diagnosis and monitoring of disease progression in the United States. It develops the Symphony Platform, a technology platform including the Symphony Fluorescence immunoanalyzer that orchestrates blood processing, biomarker isolation and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers the ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. Furthermore, he is developing biomarkers for the detection of other diseases such as hsTNT/I for myocardial damage and NT-proBNP for heart failure. It has a license and supply agreement with Toray Industries, Inc. for the manufacture and distribution of protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Get news and reviews for INVO Bioscience Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for INVO Bioscience and related companies with MarketBeat.com’s FREE daily newsletter.